Impax Laboratories, Inc, a specialty pharmaceutical company, has received US Food and Drug Administration (FDA) approval for generic Mestinon Timespan tablets (pyridostigmine bromide extended release), 180 mg. The company is going for commercialisation of this product.
[adsense:336x280:8701650588]
Mestinon Timespan tablets is indicated for the treatment of myasthenia gravis. According to IMS Health (NSP), US sales of Mestinon Timespan tablets, 180 mg were approximately $45 million for the 12 months ended July 2015. Mestinon and Timespan are registered trademarks of Valeant Pharmaceuticals International.
Subscribe to PharmaTutor News Alerts by Email >>
